Blot F, Mayaud C, Frachon I, Couderc L J, Stern M, Friard S, Caubarrère I
Service de Pneumologie, C.M.C. Foch, Suresnes.
Rev Pneumol Clin. 1995;51(6):309-20.
Cytomegalovirus (CMV) is often suspected as the causal agent in lung disease occurring in various immunodepressive states: AIDS, organ transplantation, bone marrow graft. The mechanisms involved in these three situations is however quite different. The role played by the cytopathogenic effect of the virus and the immune reaction of the host vary considerably depending on the underlying immunodepression. Thus, the criteria allowing to distinguish between CMV infection (presence of the virus or anti-CMV antibodies, no clinical signs) and CMV disease (generalized or organ specific disease resulting from the pathogenic effect of CMV replication) lack precision. The aim of this review of the literature is to assess the implicated immunovirology mechanism and thus the diagnostic (and thus therapeutic) criteria of CMV lung diseases. There is a graduation scale from AIDS, to organ transplantation and bone marrow allograft in the degree of immune reaction implicated in the lung disease and thus the need and timing of antiviral treatment. In AIDS, an interstitial pneumonia, associated with an isolation of CMV (whatever the sample origin, blood, bronchoalveolar lavage or the isolation technique) does not usually implicate treatment. Treatment may be indicated in rare cases (advanced stage immunodepression, high virus titre, endothelial involvement) or in cases in which the infection is also located in other organs. For organ transplantation, observation of CMV in blood or lavage samples in a patient with clinical or radiological signs would justify treatment. For lung transplantation, more so than for any other organ, treatment should be started early whenever respiratory signs are associated with evidence of CMV infection. Finally, in bone marrow allografts, the high rate of failure when pneumonitis has become patent implicates starting treatment immediately upon diagnosis of CMV infection. The strategy proposed here is based on a certain rationale but can be open to discussion. Controlled clinical trials are required to determine the most rigorous and coherent attitude. Finally, within the framework of the diseases examined here, search for lung disease caused by cytomegalovirus should not mask other organ localizations in, for example, the retina, the digestive tract.
巨细胞病毒(CMV)常被怀疑是各种免疫抑制状态下发生的肺部疾病的病原体,如艾滋病、器官移植、骨髓移植。然而,这三种情况下涉及的机制有很大不同。病毒的细胞致病作用和宿主的免疫反应所起的作用因潜在的免疫抑制程度而异。因此,用于区分CMV感染(病毒或抗CMV抗体存在,但无临床症状)和CMV疾病(由CMV复制的致病作用导致的全身性或器官特异性疾病)的标准缺乏精确性。这篇文献综述的目的是评估所涉及的免疫病毒学机制,从而确定CMV肺部疾病的诊断(进而治疗)标准。从艾滋病到器官移植再到骨髓同种异体移植,肺部疾病所涉及的免疫反应程度呈梯度变化,因此抗病毒治疗的必要性和时机也不同。在艾滋病中,与CMV分离(无论样本来源是血液、支气管肺泡灌洗还是分离技术)相关的间质性肺炎通常不需要治疗。在罕见情况下(晚期免疫抑制、高病毒载量、内皮细胞受累)或感染也位于其他器官的情况下,可能需要治疗。对于器官移植,在有临床或放射学症状的患者的血液或灌洗样本中观察到CMV就有理由进行治疗。对于肺移植,与其他任何器官相比,只要呼吸症状与CMV感染证据相关,就应尽早开始治疗。最后,在骨髓同种异体移植中,肺炎明显时的高失败率意味着一旦诊断出CMV感染就应立即开始治疗。这里提出的策略基于一定的原理,但可能有待讨论。需要进行对照临床试验以确定最严格和一致的态度。最后,在本文所研究疾病的框架内,寻找由巨细胞病毒引起的肺部疾病不应掩盖其他器官的定位,例如视网膜、消化道。